Retatrutide 10 mg research-grade lyophilized peptide powder in a glass vial. This compound, also known as LY3437943, is a novel peptide agonist targeting three receptors: GIP, GLP-1, and Glucagon.
Research Use Only: All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.
RESEARCH GRADE
Retatrutide 10 mg Lyophilized Powder
Form
Lyophilized peptide powder
Content
10 mg Retatrutide per vial
Packaging
Glass vial with sterile closure
Storage
Store lyophilized at 2–8 °C (desiccated, protect from light)
Molecular formula
$C_{221}H_{342}N_{46}O_{68}$
Molecular weight
~4731.4 g·mol⁻¹
Sequence
Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-γGlu-(AEEA)2-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
What is Retatrutide?
Retatrutide (LY3437943) is an investigational peptide therapeutic developed as a multi-receptor agonist. It targets the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG). By activating these three distinct pathways involved in metabolic regulation, Retatrutide is studied for its significant potential effects on weight management, glycemic control, and overall energy balance.
In laboratory studies, Retatrutide is associated with research into:
- Triple agonism of GIP, GLP-1, and Glucagon receptors
- Weight management and obesity models
- Glycemic control and Type 2 Diabetes models
- Energy expenditure and metabolic rate
- Appetite regulation
